SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Preservative-Free Ketamine

NRXP·NRx Pharmaceuticals, Inc.
MIXED
Drug Impact Rating4/10
Trial phase
Approved (ANDA)
Time to market
Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
Why 4/10
The defining binary catalyst (FDA ANDA approval) has already passed on October 30, 2026. The drug is now approved and the company is transitioning to commercial stage. No further PDUFA or pivotal readout is scheduled for this specific ANDA product in the next ~12 months. The next hard, dated catalyst is the NRX-100 NDA decision for suicidal depression (estimated ~December 2026), but that is a separate regulatory pathway. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Actionable Insight MIXED

The ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.

Price Chart

Loading chart...

Executive Summary

NRx Pharmaceuticals (NRXP) received FDA approval for its Preservative-Free Ketamine (KETAFREE) ANDA on October 30, 2026, marking the company's first approved product and its transition from a development-stage biotech to a commercial pharmaceutical company. The drug is a preservative-free formulation of IV ketamine that removes benzethonium chloride (BZT), a toxic preservative found in standard multidose vials. While the approval is a major milestone, the stock fell roughly 15% on the day (a sell-the-news reaction), and the company faces significant commercial execution risk with limited cash, no sales track record, and a pending citizen petition to ban rival BZT-containing products that remains undecided. The next major catalyst is the NRX-100 NDA for suicidal depression, with a PDUFA estimated around late 2026.

How It Works

Ketamine is a well-established generic anesthetic and pain-management drug. NRx's version removes benzethonium chloride (BZT), a preservative found in standard multidose vials that the FDA has not recognized as safe. The drug is administered intravenously and is used for anesthesia, pain management, and increasingly for psychiatric conditions such as treatment-resistant depression.

Trial Status

The FDA approved NRx's Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10 GDUFA goal date. The ANDA pathway relies on demonstrating bioequivalence to the reference listed drug rather than conducting new clinical trials. The company previously received FDA confirmation of bioequivalence, labeling alignment, and completed three commercial-scale manufacturing validation lots with two-year room-temperature stability data.

The Two-Sided Case

▲ Bull Case5
FDA approval ahead of the GDUFA goal date validates the product and clears the path to market entry, making this NRx's first approved product and transitioning the company from development-stage to commercial.
The U.S. has faced a persistent ketamine shortage since 2018, and NRx's domestically manufactured, preservative-free formulation addresses a supply gap. The company has ordered 5 million vials for launch inventory.
Analyst consensus is Strong Buy with a mean price target of $38.50 (roughly 17x the current ~$2.27 close), implying massive upside if commercial execution succeeds.
The ketamine market is valued at $750 million and projected to exceed $3 billion globally by 2034, and NRx's product is the first preservative-free formulation that avoids BZT toxicity concerns.
Institutional accumulation was strong in Q2 2026: Vanguard added 39.5%, BlackRock doubled its position, and UBS increased 1,577%. Short interest is elevated at ~23% of outstanding shares with 16.8 days to cover, creating potential for a squeeze on positive news.
▼ Bear Case5
The stock fell roughly 15% on the approval day (closed at $2.27 vs $2.66 prior), a classic 'sell the news' pattern suggesting the approval was already priced in and investors are focused on commercial execution risk.
NRx had only $26.7 million in cash as of mid-2026 and reported an $18 million net loss in the first half of 2026. Launching a generic product against entrenched competitors requires significant commercial investment and the company may need to raise capital, diluting shareholders.
The citizen petition to ban BZT-containing rival ketamine products remains pending at the FDA. If denied, NRx's preservative-free formulation will compete directly with cheaper, established generic ketamine products that already dominate the market.
As a generic ANDA product (not a novel drug with exclusivity), Preservative-Free Ketamine faces pricing pressure and can be copied by other manufacturers. There are no patent or regulatory barriers preventing competitors from launching their own preservative-free versions.
The company has no commercial track record, no sales force, and no revenue from product sales ($1.1M quarterly revenue was from other sources). Execution risk in manufacturing, distribution, and hospital formulary adoption is high.

Upcoming Catalysts

  • Commercial launch and initial sales of Preservative-Free Ketamine / KETAFREE
  • FDA decision on NRx's citizen petition to ban BZT-containing ketamine products (pending)
  • NRX-100 NDA PDUFA for suicidal depression (estimated ~December 2026)
  • Q3 2026 earnings report (scheduled November 16, 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NRx Pharmaceuticals, Inc. Press Release NRXP ·Originating report

Sources · 7

Hover a chip for the title
1 marketbeat.com2 biospace.com3 nasdaq.com4 ir.nrxpharma.com5 psychedelicalpha.com6 nrxpharma.com7 marketbeat.com